Xyzagen, Inc., announced two poster presentations highlighting its internal Kv7 research programs at the upcoming Society for Neuroscience (SfN) Annual Meeting, in Chicago, IL, Oct 4-9, 2024.
Xyzagen’s Poster Presentations at SfN
Poster Presentation # PSTR069.21 / C160 (Danshina, et. al.) “Development and Clinical Modeling of Kv7 Channel Opener Prodrug for Treatment of Neuropathic Pain”
Session PSTR069: Non-Opoid Treatment for Persistent Pain
Presentation Date & Time: Sunday, 06Oct2024, 8-9 am Central Daylight Time
Poster Presentation # PSTR205.21 / B33 (Thrasher, et. al.) “Development and Clinical Modeling of Kv7 Channel Opener Prodrug for Treatment of Focal Onset Seizures and Status Epilepticus”
Session PSTR205: Epilepsy: Human Studies
Presentation Date & Time: Monday, 07Oct2024, 4-5 pm Centra Daylight Time
About Xyzagen: Xyzagen is a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities. Our core focuses pharmacokinetic analysis, Population PK, and Quantitative Medicine utilizing AI to streamline data wrangling and querying. Our wet lab and vivarium facilities support nonGLP small and large molecule bioanalysis, in vitro ADME, nonGLP rodent safety assessments and ophthalmology, pain and neurology pharmacology. Xyzagen can integrate these services through its First-In-Rat® and First-In-Mouse® studies. The company also provides expert regulatory advice and scientific writing for IND and NDA submissions. Xyzagen not only knows how to work with small biotechs but is one as well with research on its own proprietary Kv7 ion channel opener platforms.
Xyzagen’s expertise has contributed to the FDA approval of multiple new therapeutics. For more information, visit www.xyzagen.com.
“Xyzagen” and the Xyzagen logo, First-in-Rat and First-in-Mouse are registered trademarks or trademarks of Xyzagen Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contact: Christopher Crean, Founder & CEO, Xyzagen, Inc.
Phone: 919-726-2072
Email: [email protected]
